Holen Sie sich die Stockscreener-App
17.40
9.50%
1.51
Handel nachbörslich:
17.40
Schlusskurs vom Vortag:
$15.89
Offen:
$16.15
24-Stunden-Volumen:
559.41K
Relative Volume:
1.01
Marktkapitalisierung:
$1.05B
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-214.90M
KGV:
-4.221
EPS:
-4.1222
Netto-Cashflow:
$-151.25M
1W Leistung:
+9.02%
1M Leistung:
+10.90%
6M Leistung:
-23.28%
1J Leistung:
-31.20%
1-Tages-Spanne:
$15.82
$17.42
1-Wochen-Bereich:
$14.72
$17.42
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
17.40 | 959.77M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - Newser
Will Spyre Therapeutics Inc. bounce back from current support2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - Newser
Spyre Therapeutics Inc.’s volatility index tracking explainedGlobal Markets & Risk Controlled Daily Plans - Newser
Is it time to cut losses on Spyre Therapeutics Inc.Recession Risk & Weekly Momentum Stock Picks - Newser
Real time scanner hits for Spyre Therapeutics Inc. explainedEarnings Growth Report & Risk Managed Investment Entry Signals - Newser
Natixis Advisors LLC Has $265,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Is Spyre Therapeutics Inc. forming a bottoming baseFree Breakout Entry Signal Confirmation Tool - Newser
Using flow based indicators on Spyre Therapeutics Inc.Daily Trade Monitor with Pattern Alerts - Newser
Will Spyre Therapeutics Inc. rebound enough to break evenPrice Spike Prediction for Active Traders - Newser
Is now a turning point for Spyre Therapeutics Inc.Machine Learning Stock Price Forecast Tool - Newser
Combining machine learning predictions for Spyre Therapeutics Inc.Real-Time Signal Tracking with Entry Level - Newser
Analyzing drawdowns of Spyre Therapeutics Inc. with statistical toolsChart Signal and Short-Term Forecast Tracker - Newser
What institutional flow reveals about Spyre Therapeutics Inc.Short-Term Profit Alert With Entry Forecast - Newser
Using AI based signals to follow Spyre Therapeutics Inc.Free Market Entry and Exit Point Tips - Newser
How Spyre Therapeutics Inc. stock performs during market volatilityFree Low Risk High Return Opportunities - Newser
What data driven models say about Spyre Therapeutics Inc.’s futureFree AI Driven Buy Alert Trade Blueprint - Newser
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
What’s the recovery path for long term holders of Spyre Therapeutics Inc.Daily Trade Setup Forecast with Confidence - Newser
Spyre Therapeutics Inc. Consolidation Zone May Signal AccumulationBreakout Momentum Picks With Protection Outlined - beatles.ru
What moving averages say about Spyre Therapeutics Inc.Future Growth Stock Forecasting Strategy - Newser
Will a bounce in Spyre Therapeutics Inc. offer an exitChart Confirmation Setup with ROI Signals - Newser
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionWeekly Growth Portfolio Performance Summary - Newser
Applying sector rotation models to Spyre Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Can Spyre Therapeutics Inc. expand its profit marginsFree Trading Community Access - thegnnews.com
Can momentum traders help lift Spyre Therapeutics Inc.Free Weekly Chart Analysis With Entry Advice - Newser
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows - Nasdaq
Stifel reiterates Buy rating on Spyre stock with $71 price target - Investing.com Canada
Spyre Therapeutics: Q2 Earnings Snapshot - New Haven Register
Spyre Therapeutics Reports Q2 2025 Financial Results - TipRanks
Visual trend scoring systems applied to Spyre Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
Spyre Therapeutics: A Biotech Turnaround Story? Evaluating Operational Efficiency and Earnings Resilience in a High-Risk Sector - AInvest
Spyre Therapeutics's 15min chart sees KDJ Golden Cross, Bullish Marubozu pattern confirmed. - AInvest
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):